SNGX biotech catalysts & pipeline

SOLIGENIX INC · Data as of 2026-09-08

Upcoming catalysts

SGX945 (dusquetide) — FDA meeting

2026

With these results, we intend to embark on a reformulation of SGX945 to enable home-based treatment and look forward to interacting with the health authorities in designing a follow-on placebo-controlled Phase 2b study in 2026.

Source filing

HyBryte™ (SGX301 or synthetic hypericin) — Topline data

H2 2026

In December 2024, we opened patient enrollment for our confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of CTCL with top-line results anticipated in the second half of 2026.

Source filing

Explore the free biotech catalyst calendar